GE Healthcare’s OligoProcess utilised at BioSpring facility

GE Healthcare has announced that German oligonucleotide manufacturer BioSpring has utilised its OligoProcess product as a core element of its new production facility in Frankfurt.

The fully-automated oligonucleotide synthesiser is a customisable platform for the synthesis of therapeutic oligonucleotides. It has been designed to facilitate manufacturing scale-up, from early-stage clinical research to post-marketing production on the same system.

BioSpring is the first organisation in the world to incorporate this new technology platform into a facility, a move that will enable the company to improve the output and flexibility of its manufacturing capabilities.

Oligonucleotides are short sequences of DNA or RNA that can modify the expression of genes involved in disease pathways. As such, they hold great potential for treating a wide variety of diseases such as cancer, asthma and diabetes.

Emmanuel Ligner, global BioProcess commercial manager at GE Healthcare Life Sciences, said: "With the help of our technology, BioSpring has enhanced its offering to companies needing manufacturing-scale production of oligonucleotides for therapeutic use."

Earlier this month, the company announced a new collaboration with Tesla Engineering in order to create 7.0 tesla human whole-body magnetic resonance imaging scanners for research applications.